Results 91 to 100 of about 6,696 (158)
The constant ratio combinations of dihydroartemisinin-emetine (a,b), chloroquine-emetine (c,d) and atovaquone-emetine (e,f) using CalcuSyn. Parasite viability was analysed after 72 hours using the SG-FCM method.
Jon Deakin (3813211) +4 more
core +1 more source
Emetine is an early inhibitor of HCMV replication.
A) Emetine does not inhibit HCMV entry. Cells were treated with emetine (75 nM), GCV (10 μM), and CpG 2006 (10 μM) 24 h prior to infection. Cells were infected with HCMV and treated with compounds for 90 min.
Xin Hu (38924) +14 more
core +1 more source
Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2) is the causative agent of COVID-19 pandemic, which has resulted in global fatalities since late December 2019.
Mohibullah Shah +11 more
doaj +1 more source
The expectorant action of cephaeline, emetine and 2-dehydroemetine
Cephaeline, emetine and 2-dehydroemetine were administered, as the dihydrochlorides, in doses from 0.1 to 81 mg/kg body weight, orally and subcutaneously to 135 rabbits and 92 cats arranged for the collection of respiratory tract fluid.
Lois M Knight, Eldon M Boyd
core +1 more source
The effects of emetine on the myocardium
A number of drugs have achieved notoriety for their toxicity to the myocardium. Of those used in tropical medicine antimony and emetine are outstanding examples.
Peter P. Turner
core
Cross-Family Mechanistic Analysis of Plant Alkaloids Against Neglected Arboviruses and Related RNA Viruses. [PDF]
Régis M +4 more
europepmc +1 more source
<i>FOXP3</i> deep intronic variant underlying IPEX. [PDF]
Gaufryau P +14 more
europepmc +1 more source
Emetine dihydrochloride inhibits Chikungunya virus nsP2 helicase and shows robust antiviral activity in cells and mice. [PDF]
Sharma A +9 more
europepmc +1 more source
Muscle weakness is a side effect of the chronic administration of emetine [(-)emetine] in the treatment of amoebiasis. The precise nature of the weakness is still controversial.
MITOLO CHIEPPA D. +2 more
core
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance. [PDF]
Bian H +8 more
europepmc +1 more source

